Prognostic Value and Kinetics of the PvCO2-PaCO2/CaO2-CvO2 Ratio Compared to Arterial Lactate in the Initial Phase of Septic Shock

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The ratio of the venous-arterial carbon dioxide partial pressure difference to the arteriovenous oxygen content difference (Pv-aCO₂/Ca-vO₂) may be a marker of anaerobic metabolism in patients with acute circulatory failure. This study aims to assess the prognostic value of the PvCO2-PaCO2/CaO2-CvO2 in the early phase of septic shock.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients aged over 18 years presenting with septic shock, defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia \> 2 mmol/L despite adequate fluid resuscitation. Sepsis is defined by the presence of a suspected or confirmed infectious source associated with organ dysfunction (neurological, respiratory, renal, hepatic, or hematological). \[Sepsis 3 criteria\]

Locations
Other Locations
Morocco
Avicenna Military Hospital
RECRUITING
Marrakesh
Avicenna Military Hospital
RECRUITING
Marrakesh
Department of critical care Medicine. Avicenna Military Hospital
RECRUITING
Marrakesh
Contact Information
Primary
Younes Aissaoui Professor of critical care medicine
younes.aissaoui@uca.ma
+212661403332
Backup
Ayoub Belhadj Professor of critical care medicine
ayoubbelhadj@gmail.com
+212670279562
Time Frame
Start Date: 2025-01-05
Estimated Completion Date: 2025-12
Participants
Target number of participants: 30
Treatments
Adult patients with septic shock.
Patients aged over 18 years presenting with septic shock. defined as sepsis with persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥ 65 mmHg and lactatemia \> 2 mmol/L despite adequate fluid resuscitation.
Related Therapeutic Areas
Sponsors
Leads: Avicenna Military Hospital

This content was sourced from clinicaltrials.gov